Thyroid Eye Disease, TEDNCT07056114
Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
An observational study of Thyroid Eye Disease, TED, run by Tianjin Eye Hospital at 1 site in China.
Trial summary
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the assessment of extraocular muscles fibrosis in the thyroid eye disease. Read more about this study
- Who is it for?
- Ages 20 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Thyroid Eye Disease, TED
- What is being tested?
- The patients with active or inactive TED
- How many people
- 58 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2020to 1 Jun 2025
- How long will I take part?
- 4 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit.
Who may be able to join
- Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024.
Who cannot join
- Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comprehensive Evaluation of Extraocular Muscle Fibrosis in Thyroid Eye Disease With Multi-modal Medical Images
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the assessment of extraocular muscles fibrosis in the thyroid eye disease.
Read the detailed description
Thyroid eye disease (TED) is an autoimmune orbitopathy characterized by inflammation and remodeling of the orbital tissues. These changes can lead to the development of symptoms such as proptosis, diplopia, and cosmetically disturbing. Strabismic diplopia in the active phase TED results from restriction of muscle movement due to inflammatory and oedema of extraocular muscles (EOMs). Recent studies have demonstrated that patients with active TED receiving teprotumumab experienced a meaningful improvement in proptosis and strabismic diplopia. However, there are still patients with strabismic diplopia who require strabismus surgery in the inactive phase TED. Unfortunately, the dose-response relationship in strabismus surgery for TED still exhibits significant variability, potentially leading to unsatisfactory postoperative alignment.
EOMs are manipulated mechanically during surgery for strabismus. In the progression of TED, the heterogeneity in the biomechanical properties of the EOMs caused by fibrosis may contribute to the unpredictability of strabismic diplopia. Thus, evaluating their biomechanical property changes has the potential to provide invaluable information that improves our understanding of the pathogenic mechanisms of TED-related strabismus. Real-time tissue elastography (RTE) is a noninvasive modality that provides information on periocular and ocular tissues elasticity. It could also account for strain distribution inhomogeneity across large tissue areas, potentially serving as a powerful tool for detecting and monitoring pathological processes affecting EOM stiffness.
Biomechanical property changes are often based on corresponding changes in the morphology. Orbital magnetic resonance imaging (MRI) could help to quantitatively assess the clinical activity, fibrosis and other pathological changes of TED. Studies recently reported that native T1 mapping values provide the best discrimination of morphological and fibrotic information of EOMs, and the extracellular volume (ECV) fraction is a reliable tool to quantify EOMs fibrosis. Nevertheless, the correlation of this method to relevant muscle elasticity architectures remains unavailable.
Methods Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit. Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON). Our institutional ethics committee approved all study protocols, and patients provided written informed consent.
MR image acquisition and image analysis All participants were examined using a 3.0-T MR scanner (Siemens Magnetom Verio dot, Siemens Healthcare) and a 64-channel brain coil. On the basis of a previous report, the scan sequences included routine sequences (T1-weighted sequence, T2-weighted sequence, fat-suppressed, STIR sequence) and pre/postcontrast T1 mapping using a dual-flip-angle method. Postcontrast T1 mapping was repeated in identical prescription as precontrast T1 mapping 15 min after contrast injection. The extra-cellular volume (ECV) was calculated following the previously described methodology. The region of interest (ROI) was drawn at the thickest part of the muscle and its adjacent upper and lower levels in selected axial planes, and then MRI parameters of the medial rectus (MR) and lateral rectus (LR) muscles were measured from both sides. Two independent radiologists (L.X. and J.M.) delineated ROIs on the EOMs of all participants. Three repeated measurements were performed for each muscle slice, and the mean value was used for analysis. Radiologist L.X. repeated all evaluations twice at one-month intervals to assess intraobserver reliability.
Measurement of extraocular muscles stiffness The elasticity of the extraocular muscles was assessed using an ultrasound scanner equipped with real-time tissue elastography (EUB-7500; Hitachi Medical Systems, Tokyo, Japan). The images were acquired and analyzed following the previously described methodology. The system displays real-time color-coded elastography images overlaid on B-mode ultrasound. As this provides only qualitative stiffness assessment, we used the elastic ratio method for quantitative analysis. ROI was simultaneously placed on extraocular muscles and orbital fat, and the ROI was set as large as possible (3 × 3 mm). Orbital fat elasticity was used as an internal control. Subsequently, the elastic ratio was calculated by dividing the value obtained from the extraocular muscles by that of the orbital fat. A higher elastic ratio indicates greater stiffness in the extraocular muscles, which correlates with more advanced stages of fibrosis. Two investigators performed the extraocular muscles evaluation with real-time tissue elastography. We evaluated the images only when the pressure stabilized within the optimal 5-7 bar range.
Statistical analysis Statistical analyses were conducted using SPSS version 23 (IBM, Chicago, Illinois). Continuous variables are presented as mean ± standard deviation (SD), while categorical variables are reported as frequencies and percentages. Baseline characteristics, native T1 values, and elastic ratios were compared using analysis of variance (ANOVA) for continuous variables or chi-square tests for categorical variables, as appropriate. Our study selected the medial and lateral rectus muscles for data analysis, because of their ease in sonoelastographic imaging. The association between native T1 and elastic ratio was assessed using Pearson correlation analysis. Intraobserver agreement of MR parameters and elastic ratio were assessed using Bland-Altman methods and intraclass correlation coefficients. Receiver-operating characteristic (ROC) curves were built to determine the best threshold for quantitative elastic ratio to detect extraocular muscle fibrosis. ECV cutoff value of 48% was used as standard reference to determine the best threshold for elastic ratio value to detect extraocular muscle fibrosis in inactive TED. The optimal cutoff point was identified using the Youden index. All statistical tests were two-tailed, and a P value of <0.05 was considered statistically significant.
- Conditions
- Thyroid Eye Disease, TED
- Being tested
- The patients with active or inactive TED
- Keywords
- Thyroid eye disease, Real-time tissue elastography
- Medical subject headings
- Graves Ophthalmopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The patients with active or inactive TEDOther
The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score
| Study group | Role | What they receive |
|---|---|---|
| patients group | Consecutive patients with moderate-to-severe TED Receives: Other: The patients with active or inactive TED | |
| control group | The sex-matched control group comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
MRI parameters (native T1 value and ECV) and elasticity of EOMs in the TED.
Measured: Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start1 Jan 2020
- Primary completion1 Jun 2025
- Study completion1 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid Eye Disease, TEDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 58 participants (actual)
- Target duration
- 4 Years
Sponsor and investigators
- Lead sponsor
- Tianjin Eye Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07056114
- Sponsor's protocol ID
- No.21JCYBJC01660
- Status last verified
- Jun 2025
- First submitted
- 28 Jun 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comprehensive Evaluation of Extraocular Muscle Fibrosis in Thyroid Eye Disease With Multi-modal Medical Images
- ClinicalTrials.gov ID
- NCT07056114
- Acronym / sponsor ID
- No.21JCYBJC01660
- Conditions
- Thyroid Eye Disease, TED
- Keywords
- Thyroid eye disease, Real-time tissue elastography
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 58 participants (actual)
- Lead sponsor
- Tianjin Eye HospitalUniversity, hospital or other
- Study start
- 1 Jan 2020 (actual)
- Primary completion
- 1 Jun 2025 (actual)
- Study completion
- 1 Jun 2025 (actual)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the assessment of extraocular muscles fibrosis in the thyroid eye disease.
Detailed description
Thyroid eye disease (TED) is an autoimmune orbitopathy characterized by inflammation and remodeling of the orbital tissues. These changes can lead to the development of symptoms such as proptosis, diplopia, and cosmetically disturbing. Strabismic diplopia in the active phase TED results from restriction of muscle movement due to inflammatory and oedema of extraocular muscles (EOMs). Recent studies have demonstrated that patients with active TED receiving teprotumumab experienced a meaningful improvement in proptosis and strabismic diplopia. However, there are still patients with strabismic diplopia who require strabismus surgery in the inactive phase TED. Unfortunately, the dose-response relationship in strabismus surgery for TED still exhibits significant variability, potentially leading to unsatisfactory postoperative alignment.
EOMs are manipulated mechanically during surgery for strabismus. In the progression of TED, the heterogeneity in the biomechanical properties of the EOMs caused by fibrosis may contribute to the unpredictability of strabismic diplopia. Thus, evaluating their biomechanical property changes has the potential to provide invaluable information that improves our understanding of the pathogenic mechanisms of TED-related strabismus. Real-time tissue elastography (RTE) is a noninvasive modality that provides information on periocular and ocular tissues elasticity. It could also account for strain distribution inhomogeneity across large tissue areas, potentially serving as a powerful tool for detecting and monitoring pathological processes affecting EOM stiffness.
Biomechanical property changes are often based on corresponding changes in the morphology. Orbital magnetic resonance imaging (MRI) could help to quantitatively assess the clinical activity, fibrosis and other pathological changes of TED. Studies recently reported that native T1 mapping values provide the best discrimination of morphological and fibrotic information of EOMs, and the extracellular volume (ECV) fraction is a reliable tool to quantify EOMs fibrosis. Nevertheless, the correlation of this method to relevant muscle elasticity architectures remains unavailable.
Methods Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit. Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON). Our institutional ethics committee approved all study protocols, and patients provided written informed consent.
MR image acquisition and image analysis All participants were examined using a 3.0-T MR scanner (Siemens Magnetom Verio dot, Siemens Healthcare) and a 64-channel brain coil. On the basis of a previous report, the scan sequences included routine sequences (T1-weighted sequence, T2-weighted sequence, fat-suppressed, STIR sequence) and pre/postcontrast T1 mapping using a dual-flip-angle method. Postcontrast T1 mapping was repeated in identical prescription as precontrast T1 mapping 15 min after contrast injection. The extra-cellular volume (ECV) was calculated following the previously described methodology. The region of interest (ROI) was drawn at the thickest part of the muscle and its adjacent upper and lower levels in selected axial planes, and then MRI parameters of the medial rectus (MR) and lateral rectus (LR) muscles were measured from both sides. Two independent radiologists (L.X. and J.M.) delineated ROIs on the EOMs of all participants. Three repeated measurements were performed for each muscle slice, and the mean value was used for analysis. Radiologist L.X. repeated all evaluations twice at one-month intervals to assess intraobserver reliability.
Measurement of extraocular muscles stiffness The elasticity of the extraocular muscles was assessed using an ultrasound scanner equipped with real-time tissue elastography (EUB-7500; Hitachi Medical Systems, Tokyo, Japan). The images were acquired and analyzed following the previously described methodology. The system displays real-time color-coded elastography images overlaid on B-mode ultrasound. As this provides only qualitative stiffness assessment, we used the elastic ratio method for quantitative analysis. ROI was simultaneously placed on extraocular muscles and orbital fat, and the ROI was set as large as possible (3 × 3 mm). Orbital fat elasticity was used as an internal control. Subsequently, the elastic ratio was calculated by dividing the value obtained from the extraocular muscles by that of the orbital fat. A higher elastic ratio indicates greater stiffness in the extraocular muscles, which correlates with more advanced stages of fibrosis. Two investigators performed the extraocular muscles evaluation with real-time tissue elastography. We evaluated the images only when the pressure stabilized within the optimal 5-7 bar range.
Statistical analysis Statistical analyses were conducted using SPSS version 23 (IBM, Chicago, Illinois). Continuous variables are presented as mean ± standard deviation (SD), while categorical variables are reported as frequencies and percentages. Baseline characteristics, native T1 values, and elastic ratios were compared using analysis of variance (ANOVA) for continuous variables or chi-square tests for categorical variables, as appropriate. Our study selected the medial and lateral rectus muscles for data analysis, because of their ease in sonoelastographic imaging. The association between native T1 and elastic ratio was assessed using Pearson correlation analysis. Intraobserver agreement of MR parameters and elastic ratio were assessed using Bland-Altman methods and intraclass correlation coefficients. Receiver-operating characteristic (ROC) curves were built to determine the best threshold for quantitative elastic ratio to detect extraocular muscle fibrosis. ECV cutoff value of 48% was used as standard reference to determine the best threshold for elastic ratio value to detect extraocular muscle fibrosis in inactive TED. The optimal cutoff point was identified using the Youden index. All statistical tests were two-tailed, and a P value of <0.05 was considered statistically significant.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 4 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients group | – | Other: The patients with active or inactive TEDConsecutive patients with moderate-to-severe TED |
| control group | – | –The sex-matched control group comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Study Design and Participants Consecutive patients (n=40) with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED group based on the Clinical Activity Score (CAS). The sex-matched control group (n=18) comprised healthy individuals and patients with orbital symptoms but normal findings on orbital MRI. All participants underwent a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, Hertel exophthalmometry and intraocular pressure. A blood sample was obtained on the day of MR scanning to measure hematocrit.
Key inclusion criteria (1 listed)
- Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024.
Key exclusion criteria (1 listed)
- Participants who reported any of the following were excluded: (1) any ophthalmopathies (e.g., glaucoma, diabetic retinopathy and optic nerve disorders); (2) patients with dysthyroid optic neuropathy (DON).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The patients with active or inactive TEDThe patients were categorized into either the active or inactive TED group based on the Clinical Activity Score | Other | patients group |
Primary outcome
MRI parameters (native T1 value and ECV) and elasticity of EOMs in the TED.
Time frame: Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Thyroid Eye Disease, TED
RecruitingObservational study
Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease
Graves' Orbitopathy, Thyroid Eye Disease, TED
RecruitingPhase 1
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
Thyroid Eye Disease (TED), Graves' Disease
Not yet recruitingPhase 2
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves Disease, Graves Disease (Basedow's Disease)
RecruitingPhase 3
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
Thyroid Eye Disease, TED, Graves Orbitopathy
RecruitingPhase 3
Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study
Thyroid Eye Disease, TED
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Eye Disease, TED, run by Tianjin Eye Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRI parameters (native T1 value and ECV) and elasticity of EOMs in the TED. (time frame: Consecutive patients with moderate-to-severe TED were retrospectively enrolled from Tianjin Eye Hospital between 2020 and 2024. All patients underwent MR with T1 mapping and RTE. The patients were categorized into either the active or inactive TED). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025; AzTrials last refreshed its copy on 8 Nov 2026.